001484002 000__ 04535cam\\2200553\i\4500
001484002 001__ 1484002
001484002 003__ OCoLC
001484002 005__ 20240117003310.0
001484002 006__ m\\\\\o\\d\\\\\\\\
001484002 007__ cr\un\nnnunnun
001484002 008__ 231115s2023\\\\sz\a\\\\o\\\\\001\0\eng\d
001484002 019__ $$a1409027993
001484002 020__ $$a9783031386237$$q(electronic bk.)
001484002 020__ $$a303138623X$$q(electronic bk.)
001484002 020__ $$z9783031386220
001484002 020__ $$z3031386221
001484002 0247_ $$a10.1007/978-3-031-38623-7$$2doi
001484002 035__ $$aSP(OCoLC)1409202139
001484002 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dGW5XE$$dEBLCP$$dOCLCQ$$dOCLCO
001484002 049__ $$aISEA
001484002 050_4 $$aRC280.P25
001484002 08204 $$a616.99/437$$223/eng/20231121
001484002 24500 $$aPancreatic cancer :$$bcurrent therapeutics and future directions /$$cShubham Pant, editor.
001484002 264_1 $$aCham :$$bSpringer,$$c[2023]
001484002 264_4 $$c©2023
001484002 300__ $$a1 online resource (vii, 196 pages) :$$billustrations (some color)
001484002 336__ $$atext$$btxt$$2rdacontent
001484002 337__ $$acomputer$$bc$$2rdamedia
001484002 338__ $$aonline resource$$bcr$$2rdacarrier
001484002 500__ $$aIncludes index.
001484002 5050_ $$aResectable Pancreatic Cancer: Neoadjuvant and Adjuvant Therapy -- Borderline Resectable and Locally Advanced Pancreatic Cancer -- Radiation Therapy for Pancreatic Cancer: Current and Evolving Paradigms -- Therapies for Metastatic Pancreatic Cancer -- Targeted Therapies for Pancreatic Cancer -- Immunotherapy for Pancreatic Cancer -- Liquid Biopsies for pancreatic cancer: Is it ready for prime time? -- Supportive Care challenges and management in Pancreatic Cancer -- Physical activity and nutrition optimization in pancreatic cancer.
001484002 506__ $$aAccess limited to authorized users.
001484002 520__ $$aPancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a cold, non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents. This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the Next in drug development including molecularly targeted therapy and efforts at Drugging the Undruggable: the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or liquid biopsies will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer.
001484002 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed November 21, 2023).
001484002 650_6 $$aPancréas$$xCancer.
001484002 650_6 $$aPancréas$$xCancer$$xTraitement.
001484002 650_0 $$aPancreas$$xCancer.$$0(DLC)sh 85035204
001484002 650_0 $$aPancreas$$xCancer$$xTreatment.$$0(DLC)sh 85035204
001484002 655_0 $$aElectronic books.
001484002 7001_ $$aPant, Shubham,$$eeditor.
001484002 77608 $$iPrint version: $$z3031386221$$z9783031386220$$w(OCoLC)1385291973
001484002 852__ $$bebk
001484002 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-38623-7$$zOnline Access$$91397441.1
001484002 909CO $$ooai:library.usi.edu:1484002$$pGLOBAL_SET
001484002 980__ $$aBIB
001484002 980__ $$aEBOOK
001484002 982__ $$aEbook
001484002 983__ $$aOnline
001484002 994__ $$a92$$bISE